LONDON & SAN FRANCISCO--(

伦敦和旧金山--(

BUSINESS WIRE

商业热线

)--

)--

Latent Labs

潜在实验室

, the company building AI foundation models to make biology programmable, today emerged from stealth with $50M in total funding to accelerate their progress and partnerships.

这家建立人工智能基金会模型以使生物学可编程的公司，今天从隐身中脱颖而出，获得了5000万美元的总资金，以加速他们的进步和合作伙伴关系。

The company was founded by Dr Simon Kohl, previously a co-lead of DeepMind’s protein design team and a senior research scientist on DeepMind’s AlphaFold2, the project which earned a Nobel Prize for Chemistry for Demis Hassabis and John Jumper.

该公司由西蒙·科尔（SimonKohl）博士创建，他之前是DeepMind蛋白质设计团队的联合领导者，也是DeepMind AlphaFold2的高级研究科学家，该项目为黛米斯·哈萨比斯（DemisHassabis）和约翰·霍普（JohnJupper）赢得了诺贝尔化学奖。

The funding includes a $40M Series A co-led by Radical Ventures and Sofinnova Partners, with the participation of Flying Fish, Isomer, as well as existing investors 8VC, Kindred Capital and Pillar VC.

这笔资金包括由Radical Ventures和Sofinnova Partners共同领导的4000万美元的a系列投资，Flying Fish、Isomator以及现有投资者8VC、Kindred Capital和支柱VC参与了该项目。

Notable angel investors include Google Chief Scientist Jeff Dean, Transformer architecture inventor and Cohere founder Aidan Gomez, and ElevenLabs founder Mati Staniszewski.

著名的天使投资者包括谷歌首席科学家杰夫·迪恩（JeffDean）、Transformer architecture发明家兼Cohere创始人艾丹·戈麦斯（AidanGomez）和ElevenLabs创始人马蒂·斯坦尼斯·泽夫斯基（MatiStaniszewski）。

DeepMind's AlphaFold solved the decades-old problems of protein structure prediction and showcased how machine learning can help us understand biology; now, the opportunity lies in advancing and applying the latest generative techniques to design proteins from scratch.

DeepMind的AlphaFold解决了数十年来蛋白质结构预测的问题，并展示了机器学习如何帮助我们理解生物学；现在，机会在于推进和应用最新的生成技术从头设计蛋白质。

Latent Labs

潜在实验室

’ platform does just that: by empowering researchers to computationally create new therapeutic molecules, such as antibodies or enzymes, the AI lab will help partners unlock previously challenging targets and open new paths to personalized medicines. What’s more, partners can leverage the platform to design proteins with improved molecular features (such as increased affinity and stability), expediting drug development timelines and raising success rates..

“平台正是这样做的：通过授权研究人员通过计算创建新的治疗分子，如抗体或酶，人工智能实验室将帮助合作伙伴解锁以前具有挑战性的目标，并开辟个性化药物的新途径。此外，合作伙伴可以利用该平台设计具有改进的分子特征（例如增加的亲和力和稳定性）的蛋白质，加快药物开发时间表并提高成功率。。

Latent Labs CEO and founder, Simon Kohl

潜伏实验室首席执行官兼创始人西蒙·科尔

, said: “

，表示：“

Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That's where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs.”.

每一家生物技术或制药公司都想走在技术的最前沿，寻找最佳的治疗分子，但并非所有公司都能够为此开发最先进的人工智能模型。这就是潜在实验室的由来。我们推动了生成生物学的前沿，使我们的合作伙伴能够立即获得加速其药物设计程序的工具。”。

Radical Ventures partner, Aaron Rosenberg

激进风险投资合伙人Aaron Rosenberg

, the former Head of Strategy & Operations at DeepMind, where he contributed to spinning out Isomorphic Labs to build upon AlphaFold, said: “

，DeepMind的前战略与运营负责人，他在那里为构建AlphaFold的同构实验室做出了贡献，他说：

We’ve partnered with Latent Labs because we’re confident that this team will realize the therapeutic and commercial potential of de novo protein design. Such a capability has never before been possible, one which can benefit humanity in such a profound way. Accelerating the development of more effective cures for disease, Latent is at the vanguard of innovation in computational biology, and we are excited to join them on this journey.”.

我们与潜在实验室合作，因为我们相信该团队将认识到从头蛋白质设计的治疗和商业潜力。这种能力以前是不可能的，它可以以如此深远的方式造福人类。加速开发更有效的疾病治疗方法，潜伏是计算生物学创新的先锋，我们很高兴加入他们的旅程。”。

Edward Kliphuis, partner at Sofinnova Partners

Edward Kliphuis，Sofinnova Partners合伙人

, said: '

，说：'

Latent Labs transforms biology from an observational science into an engineering craft, granting us precise control over life’s building blocks. In practical terms, it means crafting bespoke molecules that tackle challenges once thought insurmountable. It’s a revolution in our ability to harness nature’s building blocks to develop breakthrough treatments and transform our lives.

潜在实验室将生物学从观测科学转变为工程技术，使我们能够精确控制生命的组成部分。实际上，这意味着要精心定制分子，以应对曾经认为无法克服的挑战。这是我们利用大自然的积木开发突破性治疗方法并改变我们生活的能力的一场革命。

With pharmaceutical companies overwhelmingly demanding agile, next-generation tools to accelerate discovery and improve patient outcomes, Latent Labs is at the forefront of this rapidly growing market need.'.

制药公司压倒性地要求使用敏捷的下一代工具来加速发现和改善患者预后，潜在实验室处于这一快速增长的市场需求的最前沿。”。

Latent Labs has attracted world class talent, bringing experience from DeepMind, Microsoft, Google, Stability AI, Exscientia, Mammoth Bio, Altos Labs and Zymergen. The company is based in London and San Francisco, where it experimentally validates its AI platform in its lab facilities.

潜伏实验室吸引了世界一流的人才，带来了来自DeepMind、微软、谷歌、Stability AI、Exscientia、Mammoth Bio、Altos Labs和Zymergen的经验。该公司总部位于伦敦和旧金山，在实验室设施中对其AI平台进行了实验验证。

Researchers can register interest at

研究人员可以在

www.latentlabs.com

www.latentlabs.com

.

.

About Latent Labs

关于潜在实验室

Latent Labs is an AI-driven biotechnology company developing AI foundation models to make biology programmable.The company innovates on and applies generative AI technologies to enable biotechnology and pharmaceutical companies to computationally create new molecules for a range of therapeutic, industrial, and environmental uses.

潜伏实验室是一家人工智能驱动的生物技术公司，开发人工智能基础模型，使生物学可编程。该公司创新并应用生成性人工智能技术，使生物技术和制药公司能够通过计算创建用于一系列治疗，工业和环境用途的新分子。

Founded by Dr. Simon Kohl, a former DeepMind researcher and key contributor to the AlphaFold project, the company is backed by leading investors including Radical Ventures, Sofinnova Partners, 8VC, Kindred Capital, Pillar VC, Isomer and Flying Fish. Latent Labs operates globally, with offices in London and San Francisco..

该公司由前DeepMind研究员西蒙·科尔博士（SimonKohl）创建，他是AlphaFold项目的主要贡献者，该公司得到了领先投资者的支持，包括Radical Ventures、Sofinnova Partners、8VC、Kindred Capital、支柱VC、Isomer和Flying Fish。潜在实验室在全球运营，在伦敦和旧金山设有办事处。。

To join us visit:

要加入我们，请访问：

www.latentlabs.com

www.latentlabs.com